MORPHOLOGY OF ARCHEAN METABASALT FLOWS, UTIK LAKE, MANITOBAHARGREAVES R; AYRES LD.1979; CANAD. J. EARTH SCI.; CAN; DA. 1979; VOL. 16; NO 7; PP. 1452-1466; ABS. FRE; BIBL. 28 REF.Article

THE MEASURED EMISSION OF FISSION-PRODUCT GASES FROM OPERATING UO₂ FUELGREATLEY CJ; HARGREAVES R.1979; J. MATER. NUCL.; NLD; DA. 1979; VOL. 79; NO 1; PP. 235-245; BIBL. 2 REF.Article

UO₂ FUEL PERFORMANCE MODELLING AND PREDICTIVE METHODS = SIMULATION ET METHODES DE PREDICTION DES PERFORMANCES DE COMBUSTIBLE A BASE D'UO₂COLLINS DA; HARGREAVES R; HUGHES H et al.1973; IN: NUCL. FUEL PERFORMANCE. INT. CONF. PROC.; LONDON; 1973; S.L.; BR. NUCL. ENERGY SOC.; DA. 1973; PP. (5 P.); BIBL. 3 REF.Conference Paper

The Role of Molecular Imaging in Drug Discovery and DevelopmentHARGREAVES, R. J.Clinical pharmacology and therapeutics. 2008, Vol 83, Num 2, pp 349-353, issn 0009-9236, 5 p.Article

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsHESKETH, P. J; VAN BELLE, S; AAPRO, M et al.European journal of cancer (1990). 2003, Vol 39, Num 8, pp 1074-1080, issn 0959-8049, 7 p.Article

Synthesis and biological evaluation of NK₁ antagonists derived from L-tryptophanMACLEOD, A. M; CASCIERI, M. A; TATTERSALL, F. D et al.Journal of medicinal chemistry (Print). 1995, Vol 38, Num 6, pp 934-941, issn 0022-2623Article

Structural optimization affording 2-(R)-1-((R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3- oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonistHALE, J. J; MILLS, S. G; EIERMANN, G et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 23, pp 4607-4614, issn 0022-2623Article

Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonistsROWLEY, M; KULAGOWSKI, J. J; GRIMWOOD, S et al.Journal of medicinal chemistry (Print). 1997, Vol 40, Num 25, pp 4053-4068, issn 0022-2623Article

An investigation into the discriminative stimulus and reinforcing properties of the CCK_B-receptor antagonist, L-365,260 in ratsJACKSON, A; TATTERSALL, D; BENTLEY, G et al.Neuropeptides (Edinburgh). 1994, Vol 26, Num 5, pp 343-353, issn 0143-4179Article

L-687,306 : a functionally selective and potent muscarinic M₁ receptor agonistFREEDMAN, S. B; SHIL PATEL; HARGREAVES, R et al.European journal of pharmacology. 1992, Vol 215, Num 1, pp 135-136, issn 0014-2999Article

Acute Alertness-Promoting Effects of a Novel Histamine Subtype-3 Receptor Inverse Agonist in Healthy Sleep-Deprived Male VolunteersIANNONE, R; PALCZA, J; RENGER, J. J et al.Clinical pharmacology and therapeutics. 2010, Vol 88, Num 6, pp 831-839, issn 0009-9236, 9 p.Article

CD34 counts to predict the adequate collection of peripheral blood progenitor cellsARMITAGE, S; HARGREAVES, R; SAMSON, D et al.Bone marrow transplantation (Basingstoke). 1997, Vol 20, Num 7, pp 587-591, issn 0268-3369Article

Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myelomaCHAPEL, H. M; LEE, M; HARGREAVES, R et al.Lancet (British edition). 1994, Vol 343, Num 8905, pp 1059-1063, issn 0140-6736Article

Synthesis and in vitro biological of all four isomers of the potent muscarinic agonist 3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.1.]heptaneSHOWELL, G. A; BAKER, R; DAVIS, J et al.Journal of medicinal chemistry (Print). 1992, Vol 35, Num 5, pp 911-916, issn 0022-2623Article

Inhibition of the pharmacological effects of endothelinWILSON, C; HARGREAVES, R. B.Progress in medicinal chemistry. 1994, Vol 31, pp 371-410, issn 0079-6468Article

The trivial round, the common task : work and leisure on a Canterbury Hill Country Run in the 1860s and 1870sHOLLAND, P. G; HARGREAVES, R. P.New Zealand geographer. 1991, Vol 47, Num 1, pp 19-25, issn 0028-8144Article

Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in ratsMA, Q.-P; HARGREAVES, R. J.Neuroscience. 2000, Vol 101, Num 3, pp 699-707, issn 0306-4522Article

The State and housing in New Zealand to 1919HARGREAVES, R. P; HEARN, T. J; LITTLE, S et al.New Zealand geographer Auckland. 1985, Vol 41, Num 2, pp 46-55Article

Pathophysiology of migraine : New insightsHARGREAVES, R. J; SHEPHEARD, S. L.Canadian journal of neurological sciences. 1999, Vol 26, pp S12-S19, issn 0317-1671, SUP3Conference Paper

α-¹⁴C and ³⁴S isotope effects in E2 reactions of (2-phenylethyl)dimethylsulfonium ionSHUNE-LONG WU; HARGREAVES, R. T; SAUNDERS, W. H. JR et al.Journal of organic chemistry. 1985, Vol 50, Num 13, pp 2392-2394, issn 0022-3263Article

Rizatriptan has central antinociceptive effects against durally evoked responsesCUMBERBATCH, M. J; HILL, R. G; HARGREAVES, R. J et al.European journal of pharmacology. 1997, Vol 328, Num 1, pp 37-40, issn 0014-2999Article

Effect of RP 67580, a non-peptide neurokinin₁ receptor antagonist, on facilitation of a nociceptive spinal flexion reflex in the ratLAIRD, J. M. A; HARGREAVES, R. J; HILL, R. G et al.British journal of pharmacology. 1993, Vol 109, Num 3, pp 713-718, issn 0007-1188Article

Cold tests of quasi-optical gyrotron resonatorsFISCHER, R. P; HARGREAVES, R. A; FLIFLET, A. W et al.IEEE transactions on microwave theory and techniques. 1991, Vol 39, Num 6, pp 1010-1012, issn 0018-9480, 3 p.Article

Challenges in Analgesic Drug DevelopmentHEWITT, D. J; HARGREAVES, R. J; CURTIS, S. P et al.Clinical pharmacology and therapeutics. 2009, Vol 86, Num 4, pp 447-450, issn 0009-9236, 4 p.Article

Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive anti-tumor agent RH1 in human and mouse plasmaKHAN, P; ABBAS, S; HARGREAVES, R. H. J et al.Journal of chromatography. B, Biomedical sciences and applications. 1999, Vol 729, Num 1-2, pp 287-295, issn 1387-2273Article